Bharat Biotech seeks DCGI nod to conduct trials of nasal Covid-19 vaccine
Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China
BusinessToday.In | January 9, 2021 | Updated 00:19 IST
There are no intra-nasal COVID-19 vaccines under trial in India at the moment
Homegrown pharma major Bharat Biotech has sought Drug Controller General India s (DCGI) approval to conduct nasal Covid-19 vaccine trials in India. The company had received emergency approval for its Covid-19 vaccine, Covaxin, on January 3, though it is still conducting phase-3 trials in India.
There are no intra-nasal COVID-19 vaccines under trial in India at the moment. The company has developed a new single-dose nasal COVID-19 vaccine in a partnership with Washington University in St Louis, USA, which is touted to be super efficient and a game-changer.